JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals is a Japan-based research-oriented biopharmaceutical company specializing in therapies for rare and genetic diseases. Its scientific work includes biologics and a proprietary blood-brain-barrier delivery technology for central nervous system applications. The company is also involved in regenerative and other advanced medicinal approaches. Its official Japanese and English corporate information confirms headquarters in Ashiya, Hyogo, and a Tokyo Stock Exchange Prime Market listing under 4552. These capabilities support programs focused on rare genetic conditions and central nervous system delivery.
Company at a glance
Corporate information
- Company entity
- JCR Pharmaceuticals Co., Ltd.
- Headquarters / principal office
- Japan
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.jcrpharm.co.jp
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
TSE Prime: 4552
biologics · blood-brain-barrier-delivery · cell-therapy
rare-diseases · neurology
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
JCR Pharmaceuticals is a Japan-based research-oriented biopharmaceutical company specializing in therapies for rare and genetic diseases. Its scientific work includes biologics and a proprietary blood-brain-barrier delivery technology for central nervous system applications. The company is also involved in regenerative and other advanced medicinal approaches. Its official Japanese and English corporate information confirms headquarters in Ashiya, Hyogo, and a Tokyo Stock Exchange Prime Market listing under 4552. These capabilities support programs focused on rare genetic conditions and central nervous system delivery.
Business, technology & evidence
- SecuritiesTSE Prime: 4552
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · JCR Pharmaceuticals Co., Ltd. ↗JCR Pharmaceuticals Co., Ltd. ·
- Official issuer and R&D disclosure · JCR Pharmaceuticals Co., Ltd. ↗JCR Pharmaceuticals Co., Ltd. ·
- Official issuer and R&D disclosure · JCR Pharmaceuticals Co., Ltd. ↗JCR Pharmaceuticals Co., Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.